BR9906425A - Métodos para potencializar fosfato de estramustina intravenoso - Google Patents

Métodos para potencializar fosfato de estramustina intravenoso

Info

Publication number
BR9906425A
BR9906425A BR9906425-1A BR9906425A BR9906425A BR 9906425 A BR9906425 A BR 9906425A BR 9906425 A BR9906425 A BR 9906425A BR 9906425 A BR9906425 A BR 9906425A
Authority
BR
Brazil
Prior art keywords
cancer
intravenous
phosphate
stramustine phosphate
stramustine
Prior art date
Application number
BR9906425-1A
Other languages
English (en)
Inventor
Michael S Kopreski
Beryl Asp
Bo Fredhlom
Per-Ov Gunnarsson
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BR9906425A publication Critical patent/BR9906425A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Patente de Invenção:<B>"MéTODOS PARA POTENCIALIZAR FOSFATO DE ESTRAMUSTINA INTRAVENOSO"<D>. O fosfato de estramustina é uma droga quimioterapêutica anti-mitótica que provê eifcácia contra o câncer. A invenção descreve métodos que potencializam o benefício terapêutico do fosfato de estramustina intravenoso. A invenção provê fosfato de estramustina intravenoso a ser administrado em uma alta dose excedendo 1300 mg com uma dose única. O aperfeiçoamento da eficácia de farmacocinéticos de fosfato de estramustina é desse modo conseguido. Adicionalmente provido, o fosfato de estramustina pode ser intravenosamente administrado para uso em regimes de combinação com outro agente quimioterapêutico. As vantagens terapêuticas conseguidas usando a formulação de fosfato de estramustina intravenoso são aplicáveis ao tratamento de uma variedade de cânceres incluindo câncer de próstata, câncer de mama, câncer de pulmão, câncer pancreático, câncer do cólon-reto, câncer do ovário, melanoma e outros cânceres.
BR9906425-1A 1998-03-27 1999-03-26 Métodos para potencializar fosfato de estramustina intravenoso BR9906425A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7954298P 1998-03-27 1998-03-27
PCT/US1999/004275 WO1999049869A1 (en) 1998-03-27 1999-03-26 Methods to potentiate intravenous estramustine phosphate

Publications (1)

Publication Number Publication Date
BR9906425A true BR9906425A (pt) 2000-07-11

Family

ID=22151209

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9906425-1A BR9906425A (pt) 1998-03-27 1999-03-26 Métodos para potencializar fosfato de estramustina intravenoso

Country Status (16)

Country Link
EP (1) EP1003521A4 (pt)
JP (1) JP2001508810A (pt)
KR (1) KR20010021656A (pt)
CN (2) CN1273530A (pt)
AU (1) AU750010B2 (pt)
BR (1) BR9906425A (pt)
CA (1) CA2295049A1 (pt)
EA (1) EA004647B1 (pt)
HU (1) HUP0200547A3 (pt)
ID (1) ID24504A (pt)
IL (1) IL133612A0 (pt)
NO (1) NO20002343L (pt)
NZ (1) NZ501987A (pt)
PL (1) PL342969A1 (pt)
WO (1) WO1999049869A1 (pt)
ZA (1) ZA997821B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003201D0 (en) * 2000-02-11 2000-04-05 Pharmacia & Upjohn Spa Method to potentiate the therapeutic efficacy of taxane and derivatives thereof
US6436913B1 (en) * 2000-07-25 2002-08-20 Pharmacia & Upjohn Company Use of estramustine phosphate in the treatment of bone metastasis
RU2471511C1 (ru) * 2011-05-04 2013-01-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "РНИОИ" Минздравсоцразвития России) Способ лечения метастазов в печень рака толстой кишки

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS617292A (ja) * 1984-06-20 1986-01-13 Japan Atom Energy Res Inst 制癌剤を結合させたエストラサイト系化合物を製造する方法
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
WO1993018751A1 (en) * 1992-03-23 1993-09-30 Georgetown University Liposome encapsulated taxol and a method of using the same
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.

Also Published As

Publication number Publication date
HUP0200547A2 (hu) 2002-07-29
CN1636598A (zh) 2005-07-13
NO20002343D0 (no) 2000-05-04
WO1999049869A1 (en) 1999-10-07
CN1273530A (zh) 2000-11-15
PL342969A1 (en) 2001-07-16
IL133612A0 (en) 2001-04-30
EA004647B1 (ru) 2004-06-24
CA2295049A1 (en) 1999-10-07
EP1003521A1 (en) 2000-05-31
NO20002343L (no) 2000-05-04
JP2001508810A (ja) 2001-07-03
AU750010B2 (en) 2002-07-11
NZ501987A (en) 2002-10-25
ZA997821B (en) 2000-08-01
EA199901081A1 (ru) 2000-12-25
ID24504A (id) 2000-07-20
AU3353399A (en) 1999-10-18
KR20010021656A (ko) 2001-03-15
HUP0200547A3 (en) 2003-07-28
EP1003521A4 (en) 2003-07-23

Similar Documents

Publication Publication Date Title
PT988056E (pt) Metodos e composicoes de factor tecidual para o tratamento da coagulacao e de tumores
Lens et al. Systemic chemotherapy in the treatment of malignant melanoma
BR9906581A (pt) Processo para administração de taxano encapsulado em lipossomos
TR200102005T2 (tr) Poli(adp-ribaz) polimerazların trisiklik inhibitörleri.
BR0107869A (pt) Composições farmacêuticas eletrogiradas
BR0009213A (pt) Processos e composições para tratamento de tumores sólidos
Rothenberg et al. Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors
HK1046093A1 (en) Docetaxel in combination with rhumab her2 for the treatment of cancers.
BR0113447A (pt) Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
BR9916881A (pt) Métodos para tratamento do câncer ovariano, composições de poli(fosfoéster) e artigos biodegradáveis das mesmas
BRPI0516265A (pt) composição, uso da mesma, método de aumentar a retenção de um agente terapêutico dentro dos lipossomas, formulação lipossomal, e, uso de um agente terapêutico encapsulado lipossomalmente
WO2002058694A3 (en) Method of treating hematologic tumors and cancers using beta lapachone
BR0110837A (pt) Quimioterapia de combinação
WO2000066093A3 (en) Combined preparations comprising morpholine anthracyclines and anticancer agent
CA2208206A1 (en) Composition for treating tumors comprising lactose and a saccharide conjugate of a cytotoxic phenolic compound
BG106171A (en) Compositions and uses of et743 for treating cancer
Dunn et al. Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia
IL150953A0 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
BR9906425A (pt) Métodos para potencializar fosfato de estramustina intravenoso
BR0110150A (pt) Método e composição para o tratamento de câncer por meio da administração de agentes quimioterápicos indutores da apoptose
GEP20043254B (en) Use of Camptothecin Derivatives with Reduced Gastrointestinal Toxicity
BR0313048A (pt) Uso de alquilfosfocolinas em combinação com medicamentos antitumorais
Edelman et al. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy
BR0214564A (pt) Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos
CA2343120A1 (en) Use of an anthracycline derivative for the treatment of a liver tumor

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1914 DE 11/09/2007.